US Patent No: 7,968,119

Number of patents in Portfolio can not be more than 2000

Tamper-proof narcotic delivery system

ALSO PUBLISHED AS: 20030026838

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A composition for oral, transdermal or subdermal administration to a subject is described. The composition contains: (a) an agonist component; (b) an antagonist component containing at least one antagonist and having a delayed time of release; and (c) an immediate release antagonist removal component, where the subject includes a gastrointestinal tract and the antagonist removal component is present in an amount sufficient to substantially remove the antagonist component from the gastrointestinal tract of the subject before the time of release of the antagonist component. The composition may be delivered to the subject by a method which includes the step of administering the composition orally, transdermally or subdermally to the subject. When the composition of the present invention is administered orally, the method of the present invention may include the step of administering a potassium compound to the subject.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

  • Assignment data not available. Check USPTO

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Farrell, John J Norwood, MA 16 133

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (9)
5,958,452 Extruded orally administrable opioid formulations 109 1997
6,228,863 Method of preventing abuse of opioid dosage forms 102 1998
6,277,384 Opioid agonist/antagonist combinations 75 1998
6,231,886 Methods of providing sustained treatment with opioids 7 1999
6,335,033 Melt-extrusion multiparticulates 58 1999
6,261,599 Melt-extruded orally administrable opioid formulations 91 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 94 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 79 2001
2002/0058,673 Opioid agonist/opioid antagonist/acetaminophen combinations 29 2001
 
The United States of America as represented by the Secretary of the Army (2)
5,834,477 Opiate analgesic formulation with improved safety 34 1994
6,217,911 sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres 26 1996
 
VALEANT INTERNATIONAL BERMUDA (2)
5,518,730 Biodegradable controlled release flash flow melt-spun delivery system 167 1992
6,013,280 Immediate release dosage forms containing microspheres 17 1997
 
ALZA CORPORATION (1)
5,540,912 Viscous suspensions of controlled-release drug particles 76 1994
 
BAKER HUGHES INCORPORATED (1)
6,130,258 Polyvalent metal cations in combination with dithiocarbamic acid compositions as board spectrum demulsifiers 1 1998
 
BAYLOR UNIVERSITY (1)
5,855,915 Tablets or biologically acceptable implants for long-term antiinflammatory drug release 16 1996
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4,457,933 Prevention of analgesic abuse 85 1981
 
CHILDREN'S MEDICAL CENTER CORPORATION (1)
4,391,797 Systems for the controlled release of macromolecules 108 1981
 
DEXCEL PHARMA TECHNOLOGIES LTD. (1)
5,840,332 Gastrointestinal drug delivery system 65 1996
 
EDT PHARMA HOLDINGS (1)
6,066,339 Oral morphine multiparticulate formulation 10 1997
 
EURO-CELTIQUE S.A. (1)
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 54 1997
 
FUISZ TECHNOLOGIES LTD. (1)
6,020,002 Delivery of controlled-release system(s) 16 1997
 
GLYCOBIOSCIENCES INC. (1)
5,716,631 Long acting narcotic analgesics and antagonists 6 1996
 
HISAMITSU PHARMACEUTICAL CO., INC. (1)
5,820,877 Percutaneously administrable patch preparation 9 1996
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 49 1992
 
INTENSIVE NARCOTIC DETOXIFICATION CENTERS OF AMERICA, LLC (1)
5,922,705 Rapid narcotic detoxification 3 1998
 
IPSEN PHARMA S.A.S. (1)
5,569,467 Process for the preparation of microballs and microballs thus obtained 14 1994
 
JANSSEN PHARMACEUTICA N.V. (1)
5,792,477 Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent 81 1997
 
LUMARA HEALTH IP LTD. (1)
6,214,379 Maximizing effectiveness of substances used to improve health and well being 22 1999
 
Minnesota Mining and Manufacturing Company (1)
5,698,217 Transdermal drug delivery device containing a desiccant 22 1995
 
MYLAN TECHNOLOGIES, INC. (1)
5,679,373 Process of assembling a transdermal patch incorporating a polymer film incorporated with an active agent 17 1995
 
NAPP PHARMACEUTICAL GROUP LIMITED (1)
6,326,027 Controlled release formulation 61 1995
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,780,589 Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof 16 1994
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
4,906,463 Transdermal drug-delivery composition 80 1988
 
PHARMACIA & UPJOHN (1)
5,885,486 Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof 18 1996
 
QUADRANT DRUG DELIVERY LIMITED (1)
5,958,455 Oral solid dosage forms, methods of making same and compositions thereof 29 1996
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (1)
4,582,835 Analgesic compositions 89 1984
 
SIMON, DAVID LEW (1)
5,783,583 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification 7 1996
 
SS Pharmaceutical Co., Ltd. (1)
5,496,561 Controlled release-initiation and controlled release-rate pharmaceutical composition 16 1994
 
TEVA PHARMACEUTICAL INDUSTRIES LTD. (1)
5,609,886 Microspheres for the controlled release of water-soluble substances and process for preparing them 13 1995
 
The Lynx Project Limited (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 38 1997
 
The Rockefeller University (1)
4,987,136 Method for controlling gastrointestinal dysmotility 100 1986
 
UNIVERSITY OF CHICAGO, THE (1)
5,972,954 Use of methylnaltrexone and related compounds 80 1997
 
VINCENT C. GIAMPAPA (1)
5,494,677 Tissue-specific implantable therapeutic agent delivery system 6 1993
 
WILSON ELSER MOSKOWITZ EDELMAN & DICKER LLP (1)
5,709,883 Long acting narcotic analgesics and antagonists 10 1997
 
Other [Check patent profile for assignment information] (5)
5,580,569 Article for tissue-specific delivery of therapeutic agents 10 1993
5,512,587 Method for treating opiate withdrawal 1 1994
5,811,451 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies 25 1996
5,919,473 Methods and devices for delivering opioid analgesics to wounds via a subdermal implant 65 1997
6,132,416 Universal medication dosing system 13 1998

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (1)
8,758,825 Sequestered antagonist formulations 0 2013

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 28, 2014
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 28, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 28, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00

Full Text

 
loading....